Shanghai Henlius Biotech Inc. has entered into collaboration agreements with Avanc Pharma for the commercialisation of fovinaciclib citrate capsules. Under the terms of the agreements signed on December 3, 2025, Avanc Pharma will grant Henlius an exclusive license to commercialise the licensed product in designated areas and channels within China. The partnership follows a prior memorandum of cooperation and sets out arrangements for supply and commercialisation services, with Henlius handling distribution in regions where Avanc Pharma is permitted to sell the product under local policies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251203-11942832), on December 03, 2025, and is solely responsible for the information contained therein.